Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by GESINK-VAN DER VEER, B. J.
Right arrow Articles by BOVILL, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GESINK-VAN DER VEER, B. J.
Right arrow Articles by BOVILL, J. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 1993, Vol. 71, No. 6 827-834
© 1993 The Board of Management and Trustees of the British Journal of Anaesthesia

research-article

INFLUENCE OF CROHN'S DISEASE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF ALFENTANIL

B. J. GESINK-VAN DER VEER, M.D., A. G. L. BURM, M.SC., PH.D., A. A. VLETTER, B.SC. and J. G. BOVILL, M.D., PH.D., F.F.A.R.C.S.I.

Department of Anaesthesiology, University Hospital Leiden P.O. Box 9600, 2300 RC Leiden, The Netherlands

We have compared the dose requirements, pharma cokinetics and pharmacodynamics of alfentanil in 12 patients with Crohn's disease and 10 control patients undergoing abdominal surgery. Plasma concentrations of {alpha}1-acid glycoprotein (AAG) and alfentanil protein binding were also measured. Anaesthesia was induced with aifentanil 100 µg kg–1 and thiopentone, and maintained with nitrous oxide in oxygen and aifentanil 25–200 µg kg–1 h–1 Arterial blood samples were obtained before and after each change in the aifentanil infusion rate and for 6 h after stopping the infusion. Pharmacokinetic data were derived using non-compartmental methods. Alfentanil concen tration—effect data were evaluated by non-linear regression, where effect was either response or no response to surgical stimulation. Mean intra operative aifentanil requirement was greater in patients with Crohn's disease (2.48 µg kg–1 min–1) than in control patients (1.35 µg kg–1 min–1) (P< 0.01). Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg–1 min–1 and 0.70 vs 0.68 litre kg–1, respectively). Mean plasma concentration at which the probability of no response was 50% for the intra-abdominal period of surgery was greater in the Crohn group (359 ng ml–1) than in the control group (199 ng ml–1 (P<0.02). Plasma AAG concentrations were greater in the Crohn group, but the free fraction of aifentanil was similar in both groups. This study indicates that the increased alfentanil requirement in patients with Crohn's disease may be attributed to a change in pharmacodynamics. (Br. J. Anaesth. 1993; 71: 827–834)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.